Mochida Pharmaceutical Co. Ltd
Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. It offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatology, psychiatry, and gastroenterology, including Lialda, Omvoh, and Cortiment for the treatment of ulcerative colitis; Goofice and Movicol for the treatment of chronic constipation; Epadel … Read more
Mochida Pharmaceutical Co. Ltd (MFY) - Net Assets
Latest net assets as of March 2025: €130.69 Billion EUR
Based on the latest financial reports, Mochida Pharmaceutical Co. Ltd (MFY) has net assets worth €130.69 Billion EUR as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€160.12 Billion) and total liabilities (€29.43 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €130.69 Billion |
| % of Total Assets | 81.62% |
| Annual Growth Rate | 3.07% |
| 5-Year Change | 2.93% |
| 10-Year Change | 24.55% |
| Growth Volatility | 3.35 |
Mochida Pharmaceutical Co. Ltd - Net Assets Trend (2014–2025)
This chart illustrates how Mochida Pharmaceutical Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Mochida Pharmaceutical Co. Ltd (2014–2025)
The table below shows the annual net assets of Mochida Pharmaceutical Co. Ltd from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | €130.69 Billion | +2.13% |
| 2024-03-31 | €127.97 Billion | +0.94% |
| 2023-03-31 | €126.77 Billion | -1.45% |
| 2022-03-31 | €128.64 Billion | +1.32% |
| 2021-03-31 | €126.97 Billion | +5.23% |
| 2020-03-31 | €120.67 Billion | -3.55% |
| 2019-03-31 | €125.11 Billion | +4.53% |
| 2018-03-31 | €119.69 Billion | +6.99% |
| 2017-03-31 | €111.87 Billion | +6.61% |
| 2016-03-31 | €104.93 Billion | +6.34% |
| 2015-03-31 | €98.67 Billion | +5.32% |
| 2014-03-31 | €93.69 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mochida Pharmaceutical Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 27.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €116.11 Billion | 88.84% |
| Other Components | €14.58 Billion | 11.16% |
| Total Equity | €130.69 Billion | 100.00% |
Mochida Pharmaceutical Co. Ltd Competitors by Market Cap
The table below lists competitors of Mochida Pharmaceutical Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bengang Steel Plates Co Ltd
SHE:000761
|
$452.44 Million |
|
Tangel Publishing
SHE:300148
|
$453.23 Million |
|
Anpec Electronics
TWO:6138
|
$453.31 Million |
|
Xiangyu Medical Co. Ltd. A
SHG:688626
|
$453.41 Million |
|
New Pacific Metals Corp
NYSE MKT:NEWP
|
$452.28 Million |
|
Beijing Oriental Jicheng Co Ltd
SHE:002819
|
$452.07 Million |
|
Citychamp Dartong Co Ltd
SHG:600067
|
$452.04 Million |
|
Kelt Exploration Ltd
PINK:KELTF
|
$451.97 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mochida Pharmaceutical Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 127,965,000,000 to 130,693,000,000, a change of 2,728,000,000 (2.1%).
- Net income of 5,685,000,000 contributed positively to equity growth.
- Dividend payments of 2,835,000,000 reduced retained earnings.
- Share repurchases of 3,000,000 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €5.68 Billion | +4.35% |
| Dividends Paid | €2.83 Billion | -2.17% |
| Share Repurchases | €3.00 Million | -0.0% |
| Other Changes | €-119.00 Million | -0.09% |
| Total Change | €- | 2.13% |
Book Value vs Market Value Analysis
This analysis compares Mochida Pharmaceutical Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-03-31 | €2817.27 | €19.00 | x |
| 2018-03-31 | €3014.43 | €19.00 | x |
| 2019-03-31 | €3189.12 | €19.00 | x |
| 2020-03-31 | €3113.56 | €19.00 | x |
| 2021-03-31 | €3317.82 | €19.00 | x |
| 2022-03-31 | €3424.09 | €19.00 | x |
| 2023-03-31 | €3470.10 | €19.00 | x |
| 2024-03-31 | €3609.58 | €19.00 | x |
| 2025-03-31 | €3686.64 | €19.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mochida Pharmaceutical Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.41%
- • Asset Turnover: 0.66x
- • Equity Multiplier: 1.23x
- Recent ROE (4.35%) is below the historical average (6.65%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 10.56% | 10.53% | 0.72x | 1.39x | €523.20 Million |
| 2015 | 7.65% | 8.65% | 0.68x | 1.29x | €-2.32 Billion |
| 2016 | 7.77% | 8.83% | 0.67x | 1.31x | €-2.34 Billion |
| 2017 | 7.62% | 8.76% | 0.66x | 1.33x | €-2.66 Billion |
| 2018 | 7.54% | 8.45% | 0.69x | 1.30x | €-2.95 Billion |
| 2019 | 6.74% | 7.69% | 0.69x | 1.27x | €-4.08 Billion |
| 2020 | 3.81% | 4.52% | 0.65x | 1.31x | €-7.47 Billion |
| 2021 | 6.76% | 8.34% | 0.64x | 1.27x | €-4.11 Billion |
| 2022 | 8.22% | 9.59% | 0.68x | 1.27x | €-2.30 Billion |
| 2023 | 5.24% | 6.44% | 0.65x | 1.25x | €-6.03 Billion |
| 2024 | 3.55% | 4.42% | 0.65x | 1.24x | €-8.25 Billion |
| 2025 | 4.35% | 5.41% | 0.66x | 1.23x | €-7.38 Billion |
Industry Comparison
This section compares Mochida Pharmaceutical Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mochida Pharmaceutical Co. Ltd (MFY) | €130.69 Billion | 10.56% | 0.23x | $452.38 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |